Cannabigerol (CBG) was first discovered by scientists in 1964 as a component of hashish. CBG belongs to the non-psychoactive group of cannabinoids. Research into its medical properties is currently ongoing. Though it has not been studied as intensively as the other cannabinoids like CBD or THC, results obtained so far from studies suggest that it is enriched with loads of health benefits for the consumer.
Treatment for depression and anxiety: It has been proven that THC can have positive effects on patients suffering from depression. CBG has shown similar effects but without the accompanying psychotic effects that THC is known for. A 2016 report has suggested that CBG and other non-psychotic cannabinoids could effectively treat depression and anxiety.
CBG reduces inflammation by acting on special molecules that trigger the inflammatory processes in many disease states such as cancer, inflammatory bowel disease, and pain syndromes.
CBG is a cannabinoid with particular medical properties that may have beneficial health benefits for people suffering from a variety of diseases and disorders. It is apparent that with more research, development, and education, cannabinoids such as CBG, could offer safer, more natural disease-targeted alternatives to conventional treatments.
ChemIDplus Chemical Information Classification
Ranja, AG.; Carrillo-Salinas, F.; Pagani, A.; Gómez-Cañas, M.; Negri, R.; Navarrete, C.; Mecha, M.; Mestre, L.; Fiebich, BL.; Cantarero, I.; Calzado, MA.; Bellido, ML.; Fernandez-Ruiz, J.; Appendino, G.; Guaza, C.; Muñoz, E. (2012). “A cannabigerol quinone alleviates neuroinflammation in a chronic model of multiple sclerosis”. J Neuroimmune Pharmacol. 7 (4): 1002–16. doi:10.1007/s11481-012-9399-3. PMID22971837.
Hala N. Eisohly, Carlton E. Turner, Alice M. Clark, Mahmoud A. Eisohly (1982). Synthesis and antimicrobial activities of certain cannabichromene and cannabigerol related compounds
George ANASTASSOV, Lekhram Changoer (2014). Oral care composition comprising cannabinoids